Tuesday, January 08, 2019 5:03:49 PM
Around one-fifth of the office’s workforce will focus on creating more structured approaches to the evaluation of biomarkers, which Gottlieb thinks are ready to play a “much more formal” role in drug development and review. One strand of the biomarker unit’s activities will seek to develop standards in collaboration with drug developers, academics and other stakeholders.
Another third of the office’s 51 employees will work on biomedical informatics and safety analytics. Gottlieb said these staff will build “a standardized tool for capturing and formatting safety data” to make the agency’s reviews of safety data more structured and consistent.
If the initiative advances as hoped, it will serve as a stepping stone to a new way of managing drug application reviews. The new approach foreseen by Gottlieb will build on advances in data handling and cloud computing to give the FDA a more active role in how the information underpinning filings is presented and evaluated.
“Applications will be cloud based and instead of taking the sponsors' charts and tables and evaluating their charts and tables, we’ll be pulling down their bottom line data and formatting it through our own assessment tools and creating our own charts and tables to do the evaluation,” Gottlieb said.
Recent KNW News
- Know Labs to Present Clinical Research at the 2024 American Physiology Summit • Business Wire • 04/05/2024 01:00:00 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 03/06/2024 09:15:34 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/06/2024 09:10:40 PM
- Know Labs’ Non-Invasive Glucose Monitor Achieves 11.1% MARD in Latest Clinical Research Study • Business Wire • 03/06/2024 02:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/29/2024 09:17:42 PM
- Know Labs Secures U.S. $12 Million Funding for Company’s Further Execution on Its Clinical Research and Development Initiatives • Business Wire • 02/29/2024 09:15:00 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 04:44:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2024 02:03:51 PM
- Know Labs Announces the KnowU™, its Wearable Non-Invasive Continuous Glucose Monitor • Business Wire • 02/27/2024 02:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:17:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/14/2024 09:15:26 PM
- Know Labs, Inc. Reports First Quarter FY2024 Results • Business Wire • 02/14/2024 09:15:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:23:34 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:22:29 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:20:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:19:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:18:16 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/09/2024 09:17:03 PM
- Know Labs, Inc. to Host Review of First Quarter Fiscal Year 2024 Results on February 14, 2024 • Business Wire • 02/07/2024 02:00:00 PM
- Know Labs to Exhibit at the 17th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) • Business Wire • 01/23/2024 02:00:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 01/12/2024 05:15:08 AM
- Form S-3/A - Registration statement under Securities Act of 1933: [Amend] • Edgar (US Regulatory) • 01/05/2024 09:16:39 PM
- Form S-3 - Registration statement under Securities Act of 1933 • Edgar (US Regulatory) • 12/22/2023 09:15:52 PM
- Know Labs, Inc. Reports Fourth Quarter and Fiscal Year 2023 Results • Business Wire • 12/19/2023 09:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 12/19/2023 09:03:19 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM